,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,485,1,8,,26719722,2585,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
1,485,1,8,,26719723,2585,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
2,631,1,4,,26719722,2585,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
3,631,1,4,,26719722,2585,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
4,631,1,4,,26719723,2585,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
5,631,1,4,,26719723,2585,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
6,731,1,5,,26719722,2585,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
7,731,1,5,,26719722,2585,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
8,731,1,5,,26719723,2585,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
9,731,1,5,,26719723,2585,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
10,781,1,1,,26719722,2585,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
11,781,1,1,,26719723,2585,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
12,782,1,2,,26719722,2585,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
13,782,1,2,,26719722,2585,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
14,782,1,2,,26719723,2585,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
15,782,1,2,,26719723,2585,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
16,880,2,1,,26719722,2585,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
17,880,2,1,,26719722,2585,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
18,880,2,1,,26719723,2585,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
19,880,2,1,,26719723,2585,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
20,950,1,1,,26719722,2585,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
21,950,1,1,,26719723,2585,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
22,951,1,1,,26719722,2585,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
23,951,1,1,,26719723,2585,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
24,952,1,1,,26719722,2585,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
25,952,1,1,,26719723,2585,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
26,1001,2,2,,26719722,2585,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
27,1006,1,6,,26719722,2585,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
28,1007,1,1,,26719722,2585,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
29,1007,1,1,,26719723,2585,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
30,1008,1,2,,26719722,2585,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
31,1008,1,2,,26719723,2585,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
32,1009,1,2,,26719722,2585,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
33,1009,1,2,,26719723,2585,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
34,1012,1,4,,26719722,2585,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
35,1016,1,4,,26719722,2585,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
36,1018,2,5,,26719722,2585,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
37,1019,1,4,,26719722,2585,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
38,1020,1,5,,26719722,2585,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
39,1021,1,1,,26719722,2585,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
40,1021,1,1,,26719723,2585,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
41,1022,1,1,,26719722,2585,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
42,1022,1,1,,26719723,2585,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
43,1027,1,3,,26719722,2585,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
44,1032,1,2,,26719722,2585,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
45,1032,1,2,,26719722,2585,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
46,1032,1,2,,26719723,2585,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
47,1032,1,2,,26719723,2585,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
48,1040,1,2,,26719722,2585,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
49,1040,1,2,,26719723,2585,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
50,1048,1,1,,26719722,2585,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
51,1048,1,1,,26719722,2585,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
52,1048,1,1,,26719723,2585,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
53,1048,1,1,,26719723,2585,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
54,1049,1,1,,26719722,2585,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
55,1049,1,1,,26719722,2585,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
56,1049,1,1,,26719723,2585,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
57,1049,1,1,,26719723,2585,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
58,1051,1,1,,26719722,2585,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
59,1051,1,1,,26719722,2585,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
60,1051,1,1,,26719723,2585,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
61,1051,1,1,,26719723,2585,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
62,1066,1,2,,26719722,2585,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
63,1066,1,2,,26719723,2585,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
64,1085,1,1,,26719722,2585,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
65,1085,1,1,,26719723,2585,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
66,1135,1,3,,26719722,2585,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
67,1136,1,3,,26719722,2585,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
68,1195,1,2,,48415707,2585,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
69,1203,1,3,,26719722,2585,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
70,1203,1,3,,26719723,2585,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
71,1209,2,2,,26719722,2585,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
72,1214,1,4,,26719722,2585,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
73,1216,1,5,,26719722,2585,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
74,1217,1,4,,26719722,2585,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
75,1220,2,2,,26719722,2585,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
76,1222,1,6,,26719722,2585,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
77,1229,1,3,,26719722,2585,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
78,1236,1,1,,26719722,2585,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
79,1236,1,1,,26719723,2585,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
80,1251,1,1,,26719722,2585,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
81,1251,1,1,,26719723,2585,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
82,1274,1,2,,26719722,2585,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
83,1274,1,2,,26719723,2585,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
84,1304,1,2,,26719722,2585,Active,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
85,1304,1,2,,26719723,2585,Active,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
86,1321,1,2,,26719722,2585,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
87,1321,1,2,,26719723,2585,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
88,1325,1,2,,26719722,2585,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
89,1325,1,2,,26719723,2585,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
90,1359,1,4,,26719722,2585,Active,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
91,1359,1,4,,26719723,2585,Active,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
92,1362,1,2,,26719722,2585,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
93,1362,1,2,,26719723,2585,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
94,1376,1,2,,49681735,2585,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
95,1385,2,2,,49681735,2585,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
96,1415,1,2,,26719722,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
97,1415,1,2,,26719722,2585,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
98,1415,1,2,,26719723,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
99,1415,1,2,,26719723,2585,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
100,1416,1,2,,26719722,2585,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
101,1416,1,2,,26719723,2585,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
102,1422,1,1,,49681735,2585,Active,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
103,1423,1,2,,26719722,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
104,1423,1,2,,26719722,2585,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
105,1423,1,2,,26719723,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
106,1423,1,2,,26719723,2585,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
107,1424,1,1,,26719722,2585,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
108,1424,1,1,,26719723,2585,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
109,1434,2,3,,26719722,2585,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
110,1434,2,3,,26719722,2585,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
111,1439,1,1,,26719722,2585,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
112,1439,1,1,,26719722,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
113,1439,1,1,,26719723,2585,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
114,1439,1,1,,26719723,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
115,1440,1,1,,26719722,2585,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
116,1440,1,1,,26719722,2585,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
117,1440,1,1,,26719723,2585,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
118,1440,1,1,,26719723,2585,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
119,1441,1,1,,26719722,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
120,1441,1,1,,26719722,2585,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
121,1441,1,1,,26719723,2585,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
122,1441,1,1,,26719723,2585,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
123,1443,1,3,,26719722,2585,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
124,1445,1,1,,26719722,2585,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
125,1445,1,1,,26719723,2585,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
126,1446,1,3,,26719722,2585,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
127,1446,1,3,,26719723,2585,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
128,1448,1,3,,26719722,2585,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
129,1448,1,3,,26719723,2585,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
130,1454,1,1,,26719722,2585,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
131,1454,1,1,,26719723,2585,Inconclusive,66932916.0,5594.0,39.8107,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
132,1456,1,1,,26719722,2585,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
133,1456,1,1,,26719723,2585,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
134,1460,1,3,,26719722,2585,Inconclusive,92096784.0,4137.0,22.3872,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
135,1460,1,3,,26719723,2585,Inconclusive,92096784.0,4137.0,22.3872,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
136,1461,1,2,,26719722,2585,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
137,1461,1,2,,26719723,2585,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
138,1463,1,1,,26719722,2585,Inconclusive,,,17.7828,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
139,1463,1,1,,26719723,2585,Inconclusive,,,22.3872,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
140,1465,1,1,,49681735,2585,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
141,1466,1,2,,26719722,2585,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
142,1466,1,2,,26719723,2585,Inconclusive,119393891.0,2548.0,11.2202,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
143,1467,1,3,,26719722,2585,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
144,1467,1,3,,26719723,2585,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
145,1468,1,1,,26719722,2585,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
146,1468,1,1,,26719723,2585,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
147,1469,1,1,,26719722,2585,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
148,1469,1,1,,26719723,2585,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
149,1469,1,1,,50112972,2585,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
150,1477,1,1,,26719722,2585,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
151,1477,1,1,,26719723,2585,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
152,1477,1,1,,50112972,2585,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
153,1479,1,2,,26719722,2585,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
154,1479,1,2,,26719723,2585,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
155,1479,1,2,,50112972,2585,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
156,1481,1,2,,26719722,2585,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
157,1481,1,2,,26719723,2585,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
158,1486,1,3,,26719722,2585,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
159,1486,1,3,,26719723,2585,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
160,1487,1,1,,26719723,2585,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
161,1490,2,1,,26719722,2585,Active,10954339.0,,50.1187,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
162,1490,2,1,,26719723,2585,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
163,1490,2,1,,50112972,2585,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
164,1496,1,4,,26719722,2585,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
165,1496,1,4,,26719722,2585,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
166,1509,1,2,,26719722,2585,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
167,1509,1,2,,26719723,2585,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
168,1510,1,3,,26719722,2585,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
169,1510,1,3,,26719723,2585,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
170,1511,1,3,,49681735,2585,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
171,1515,1,2,,26719722,2585,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
172,1515,1,2,,26719723,2585,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
173,1527,1,3,,26719722,2585,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
174,1527,1,3,,26719723,2585,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
175,1529,1,1,,26719722,2585,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
176,1529,1,1,,26719723,2585,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
177,1529,1,1,,49681735,2585,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
178,1530,1,1,,26719722,2585,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
179,1530,1,1,,26719723,2585,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
180,1530,1,1,,49681735,2585,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
181,1531,1,1,,26719722,2585,Active,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
182,1531,1,1,,26719723,2585,Active,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
183,1531,1,1,,49681735,2585,Active,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
184,1532,1,1,,49681735,2585,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
185,1533,1,1,,26719722,2585,Inactive,15610402.0,888704.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
186,1533,1,1,,26719722,2585,Inactive,15610601.0,887352.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
187,1554,1,1,,49681735,2585,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
188,1556,1,4,,26719722,2585,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
189,1556,1,4,,26719723,2585,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
190,1565,2,2,,26719722,2585,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
191,1566,2,3,,26719722,2585,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
192,1578,3,2,,26719722,2585,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
193,1619,1,2,,26719722,2585,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
194,1619,1,2,,26719723,2585,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
195,1621,1,2,,49681735,2585,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
196,1625,2,2,,26719722,2585,Inactive,,,,EC50,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
197,1626,1,2,,26719722,2585,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
198,1626,1,2,,26719723,2585,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
199,1626,1,2,,49681735,2585,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
200,1628,2,2,,26719722,2585,Inactive,,,,IC50,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
201,1631,3,1,,26719722,2585,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
202,1631,3,1,,26719723,2585,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
203,1634,3,1,,26719722,2585,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
204,1634,3,1,,26719723,2585,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
205,1654,2,2,,26719722,2585,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
206,1656,2,2,,26719722,2585,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
207,1662,1,2,,49681735,2585,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
208,1663,1,2,,49681735,2585,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
209,1665,2,2,,26719722,2585,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
210,1672,1,3,,49681735,2585,Active,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
211,1700,1,2,,26719722,2585,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
212,1700,1,2,,26719723,2585,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
213,1706,1,2,,26719722,2585,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
214,1706,1,2,,26719723,2585,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
215,1721,1,2,,26719722,2585,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
216,1721,1,2,,26719723,2585,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
217,1722,1,2,,26719722,2585,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
218,1722,1,2,,26719723,2585,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
219,1766,1,1,,26719722,2585,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
220,1766,1,1,,26719722,2585,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
221,1766,1,1,,26719723,2585,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
222,1766,1,1,,26719723,2585,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
223,1766,1,1,,50112972,2585,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
224,1766,1,1,,50112972,2585,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
225,1768,1,1,,26719722,2585,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
226,1768,1,1,,26719722,2585,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
227,1768,1,1,,26719723,2585,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
228,1768,1,1,,26719723,2585,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
229,1768,1,1,,50112972,2585,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
230,1768,1,1,,50112972,2585,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
231,1775,1,2,,26719722,2585,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
232,1775,1,2,,26719723,2585,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
233,1776,1,2,,26719722,2585,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
234,1776,1,2,,26719723,2585,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
235,1777,3,2,,26719722,2585,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
236,1778,3,3,,26719722,2585,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
237,1779,2,2,,26719722,2585,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
238,1789,1,2,,26719722,2585,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
239,1789,1,2,,26719723,2585,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
240,1800,1,2,,26719722,2585,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
241,1800,1,2,,26719723,2585,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
242,1813,1,2,,49681735,2585,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
243,1814,1,2,,49681735,2585,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
244,1817,2,2,,26719722,2585,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
245,1822,1,3,,26719722,2585,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
246,1822,1,3,,26719723,2585,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
247,1825,1,1,,26719722,2585,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
248,1825,1,1,,26719723,2585,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
249,1832,2,1,,49681735,2585,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
250,1845,1,2,,26719722,2585,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
251,1845,1,2,,26719723,2585,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
252,1850,2,1,,49681735,2585,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
253,1861,2,1,,26719722,2585,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
254,1861,2,1,,26719723,2585,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
255,1863,2,1,,26719722,2585,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
256,1863,2,1,,26719723,2585,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
257,1863,2,1,,49681735,2585,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
258,1865,1,1,,26719722,2585,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
259,1865,1,1,,26719723,2585,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
260,1868,1,4,,26719722,2585,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
261,1868,1,4,,26719723,2585,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
262,1875,2,1,,49681735,2585,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
263,1885,2,1,,49681735,2585,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
264,1892,1,1,,49681735,2585,Inactive,22035600.0,5871.0,,,"Single Concentration Confirmation Screen via Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
265,1893,1,1,,49681735,2585,Inactive,22035600.0,5871.0,,,"Single Concentration Confirmation Screen via Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
266,1894,1,1,,49681735,2585,Inactive,42794767.0,4215.0,,,"Single Concentration Confirmation Screen via Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
267,1899,1,3,,49681735,2585,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
268,1903,2,3,,26719722,2585,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
269,1903,2,3,,26719723,2585,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
270,1903,2,3,,49681735,2585,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
271,1906,1,3,,49681735,2585,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
272,1910,1,2,,49681735,2585,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
273,1947,1,2,,49681735,2585,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
274,1950,1,3,,49681735,2585,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
275,1956,1,1,,49681735,2585,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
276,1961,2,2,,26719722,2585,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
277,1962,1,2,,49681735,2585,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
278,1974,1,2,,49681735,2585,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
279,1979,1,1,,49681735,2585,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
280,1984,1,3,,26719722,2585,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
281,1986,1,2,,26719722,2585,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
282,1987,1,2,,49681735,2585,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
283,2006,3,2,,26719722,2585,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
284,2006,3,2,,26719722,2585,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
285,2006,3,2,,26719722,2585,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
286,2012,3,2,,26719722,2585,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
287,2013,2,2,,26719722,2585,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
288,2014,3,2,,26719722,2585,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
289,2016,1,3,,49681735,2585,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
290,2023,1,3,,49681735,2585,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
291,2025,1,3,,49681735,2585,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
292,2029,1,3,,49681735,2585,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
293,2052,2,1,,49681735,2585,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
294,2057,1,2,,49681735,2585,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
295,2058,3,2,,26719722,2585,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
296,2062,1,2,,85209910,2585,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
297,2066,1,4,,49681735,2585,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
298,2071,2,2,,26719722,2585,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
299,2073,2,3,,26719722,2585,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
300,2073,2,3,,26719722,2585,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
301,2094,1,2,,49681735,2585,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
302,2094,1,2,,49681735,2585,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
303,2094,1,2,,49681735,2585,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
304,2097,1,2,,49681735,2585,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
305,2098,1,1,,49681735,2585,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
306,2099,1,1,,49681735,2585,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
307,2100,1,1,,26719722,2585,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
308,2100,1,1,,26719723,2585,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
309,2101,1,1,,26719722,2585,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
310,2101,1,1,,26719723,2585,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
311,2101,1,1,,50112972,2585,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
312,2107,1,1,,26719722,2585,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
313,2107,1,1,,26719723,2585,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
314,2107,1,1,,50112972,2585,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
315,2112,1,1,,26719722,2585,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
316,2112,1,1,,26719723,2585,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
317,2112,1,1,,50112972,2585,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
318,2129,1,2,,49681735,2585,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
319,2130,1,3,,49681735,2585,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
320,2147,1,1,,26719722,2585,Active,221046486.0,,25.1189,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
321,2147,1,1,,26719723,2585,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
322,2156,2,2,,49681735,2585,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
323,2174,1,3,,49681735,2585,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
324,2177,1,3,,49681735,2585,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
325,2216,1,3,,49681735,2585,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
326,2221,1,2,,49681735,2585,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
327,2227,1,2,,49681735,2585,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
328,2234,1,2,,49681735,2585,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
329,2235,1,2,,49681735,2585,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
330,2237,1,2,,49681735,2585,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
331,2239,1,2,,49681735,2585,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
332,2240,1,1,,85789708,2585,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
333,2241,1,1,,85789708,2585,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
334,2242,1,1,,26719722,2585,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
335,2242,1,1,,26719723,2585,Inconclusive,119393891.0,2548.0,11.2202,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
336,2247,1,2,,49681735,2585,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
337,2275,1,1,,85789708,2585,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
338,2280,2,3,,49681735,2585,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
339,2288,1,1,,26719722,2585,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
340,2288,1,1,,26719723,2585,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
341,2289,1,1,,26719722,2585,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
342,2289,1,1,,26719723,2585,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
343,2300,1,3,,49681735,2585,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
344,2313,1,1,,85789708,2585,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
345,2314,1,2,,26719722,2585,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
346,2314,1,2,,26719722,2585,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
347,2314,1,2,,26719723,2585,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
348,2314,1,2,,26719723,2585,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
349,2314,1,2,,50112972,2585,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
350,2314,1,2,,50112972,2585,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
351,2315,1,2,,26719722,2585,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
352,2315,1,2,,26719722,2585,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
353,2315,1,2,,26719723,2585,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
354,2315,1,2,,26719723,2585,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
355,2315,1,2,,50112972,2585,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
356,2315,1,2,,50112972,2585,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
357,2322,1,1,,85789708,2585,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
358,2330,1,1,,85789708,2585,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
359,2380,1,2,,49681735,2585,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
360,2391,1,1,,49681735,2585,Inconclusive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
361,2435,1,2,,49681735,2585,Active,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
362,2445,1,2,,49681735,2585,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
363,2451,1,2,,26719722,2585,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
364,2451,1,2,,26719723,2585,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
365,2451,1,2,,50112972,2585,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
366,2462,1,1,,49681735,2585,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
367,2462,1,1,,49681735,2585,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
368,2472,1,2,,26719722,2585,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
369,2472,1,2,,26719723,2585,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
370,2472,1,2,,50112972,2585,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
371,2517,2,1,,26719722,2585,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
372,2517,2,1,,26719723,2585,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
373,2517,2,1,,50112972,2585,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
374,2520,1,4,,49681735,2585,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
375,2521,1,3,,49681735,2585,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
376,2524,1,2,,49681735,2585,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
377,2528,1,2,,26719722,2585,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
378,2528,1,2,,26719723,2585,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
379,2528,1,2,,50112972,2585,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
380,2540,1,2,,49681735,2585,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
381,2544,1,2,,49681735,2585,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
382,2546,1,1,,26719722,2585,Inconclusive,188536040.0,19885.0,15.8489,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
383,2546,1,1,,26719723,2585,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
384,2546,1,1,,50112972,2585,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
385,2549,1,1,,26719722,2585,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
386,2549,1,1,,26719723,2585,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
387,2549,1,1,,50112972,2585,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
388,2550,1,3,,49681735,2585,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
389,2551,1,1,,26719722,2585,Active,188536040.0,19885.0,1.0,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
390,2551,1,1,,26719723,2585,Inconclusive,188536040.0,19885.0,15.8489,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
391,2551,1,1,,50112972,2585,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
392,2553,1,2,,49681735,2585,Active,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
393,2557,1,3,,49681735,2585,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
394,2563,1,1,,49681735,2585,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
395,2599,1,2,,49681735,2585,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
396,2606,1,2,,49681735,2585,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
397,2629,1,1,,49681735,2585,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
398,2642,1,2,,49681735,2585,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
399,2648,1,2,,49681735,2585,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
400,2650,2,1,,49681735,2585,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
401,2660,1,1,,90341342,2585,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
402,2661,1,1,,49681735,2585,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
403,2662,2,1,,26719722,2585,Inconclusive,56550039.0,4297.0,25.1189,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
404,2662,2,1,,26719723,2585,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
405,2666,1,1,,90341342,2585,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
406,2667,1,1,,90341342,2585,Inconclusive,4826730.0,2475.0,14.6892,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
407,2668,1,1,,90341342,2585,Inconclusive,4826730.0,2475.0,14.6892,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
408,2675,1,1,,26719722,2585,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
409,2675,1,1,,26719723,2585,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
410,2676,1,2,,26719722,2585,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
411,2676,1,2,,26719723,2585,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
412,2685,1,1,,26719722,2585,Inconclusive,,,32.6427,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
413,2685,1,1,,26719723,2585,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
414,2690,1,2,,49681735,2585,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
415,2696,1,1,,49681735,2585,Active,160333370.0,22068.0,44.67,EC50,Confirmation dose response assay for compounds that inhibit transient receptor potential cation channel C6 (TRPC6).,Confirmatory,,
416,2716,1,1,,49681735,2585,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
417,2717,1,2,,49681735,2585,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
418,2718,1,1,,49681735,2585,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
419,2732,1,1,,26719722,2585,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
420,2732,1,1,,26719723,2585,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
421,2751,2,2,,49681735,2585,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
422,2776,1,2,,49681735,2585,Active,2935630.0,22066.0,,,Second specificity screen against TRPC4 for compounds that inhibit transient receptor potential cation   channel C6 (TRPC6),Screening,,
423,2777,1,2,,49681735,2585,Inactive,2935630.0,22066.0,,,Specificity screen against TRPC4 for compounds that inhibit transient receptor potential   cation channel C6 (TRPC6),Screening,,
424,2779,1,1,,49681735,2585,Inactive,,,,,Second counter screen for compounds that inhibit transient receptor potential cation   channel C6 (TRPC6),Screening,,
425,2780,1,1,,49681735,2585,Inactive,,,,,Counter screen for compounds that inhibit transient receptor potential cation channel C6   (TRPC6),Screening,,
426,2796,1,4,,49681735,2585,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
427,2797,1,2,,49681735,2585,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
428,2805,2,2,,49681735,2585,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
429,2806,2,2,,49681735,2585,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
430,2825,1,2,,49681735,2585,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
431,4411,5,1,,103197484,2585,Active,,,0.00316,Ki,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Confirmatory,8568799.0,
432,27167,3,4,,103197484,2585,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
433,28681,3,4,,103197484,2585,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
434,29359,3,3,,103197484,2585,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
435,29812,3,3,,103197484,2585,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
436,41895,3,7,,103197484,2585,Unspecified,,,,,Beta-blocking activity was measured by applying the stepwise linear discriminate analysis; Active,Other,,
437,161281,10,5,,103197484,2585,Active,7531135.0,3757.0,10.4713,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
438,217926,8,2,,103197484,2585,Active,,,1.7,IC50,Inhibition of [3H]BTX binding to cardiac voltage-gated sodium channel,Confirmatory,11170622.0,
439,217930,6,2,,103197484,2585,Active,,,0.306,IC50,Inhibition of veratridine-induced guanidine flux in cardiac voltage-gated sodium channel (veratridine block vs. Na release),Confirmatory,11170622.0,
440,218991,3,3,,103197484,2585,Unspecified,,,,,Oxidation was assessed indirectly by measuring bovine serum albumin (BSA) thiol protection from the formation of thiobarbituric acid reactive substances (TBARs) by TBARs test at 10 uM,Other,11755356.0,
441,218993,3,3,,103197484,2585,Unspecified,,,,,Oxidation was assessed indirectly by measuring bovine serum albumin thiol protection by using Ellman''s test at 1 mM,Other,11755356.0,
442,218994,3,3,,103197484,2585,Unspecified,,,,,Oxidation was assessed indirectly by measuring bovine serum albumin thiol protection by using Ellman''s test at 500 uM,Other,11755356.0,
443,218995,3,3,,103197484,2585,Unspecified,,,,,Oxidation was assessed indirectly by measuring bovine serum albumin(BSA) thiol protection from the formation of thiobarbituric acid reactive substances (TBARs) by TBARs test at 100 uM,Other,11755356.0,
444,218997,3,3,,103197484,2585,Unspecified,,,,,Oxidation was assessed indirectly by measuring bovine serum albumin(BSA) thiol protection from the formation of thiobarbituric acid reactive substances (TBARs) by TBARs test at 500 uM,Other,11755356.0,
445,240820,9,2,,103197484,2585,Active,,,0.35,IC50,Inhibitory concentration against IKr potassium channel,Confirmatory,15324906.0,
446,243151,7,2,,103197484,2585,Active,,,10.4713,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
447,302758,4,2,,103197484,2585,Active,,,,,Solubility by shake flask method,Other,17929794.0,
448,312895,3,4,,103197484,2585,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18189348.0,
449,312896,3,4,,103197484,2585,Unspecified,,,,,"Partition coefficient, log P by UPLC method",Other,18189348.0,
450,350216,3,3,,103197484,2585,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19397318.0,
451,350217,3,3,,103197484,2585,Unspecified,,,,,"Octanol-water partition coefficient, log Pn of the compound",Other,19397318.0,
452,350218,3,4,,103197484,2585,Unspecified,,,,,"Octanol-water partition coefficient, log PC of the compound",Other,19397318.0,
453,350219,3,4,,103197484,2585,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase",Other,19397318.0,
454,350220,3,4,,103197484,2585,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase",Other,19397318.0,
455,373867,6,3,,103197484,2585,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
456,389416,8,5,,103197484,2585,Inconclusive,296439450.0,154.0,,Ki,Displacement of [3H]DHA from human beta2 adrenoceptor by liquid scintillation counter,Confirmatory,18829308.0,
457,408340,8,5,,103197484,2585,Active,7531135.0,3757.0,10.4713,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
458,411793,6,2,,103197484,2585,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein,Other,19108654.0,
459,416873,4,3,,103197484,2585,Active,,,0.0022,Ki,Displacement of [3H]prazosin from alpha1 adrenergic receptor in rat cerebral cortex by liquid scintillation method,Confirmatory,18599160.0,
460,416874,4,3,,103197484,2585,Active,,,0.0034,Ki,Displacement of [3H]clonidine from alpha2 adrenergic receptor in rat cerebral cortex by liquid scintillation method,Confirmatory,18599160.0,
461,416875,8,5,,103197484,2585,Active,114754.0,24925.0,0.00081,Ki,Displacement of [3H]CGP12177 from beta-1 adrenergic receptor in rat cerebral cortex by liquid scintillation method,Confirmatory,18599160.0,
462,416876,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in P-Q interval at 1 mg/kg, iv after 1 min by electrocardiography",Other,18599160.0,
463,416877,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in QRS interval at 1 mg/kg, iv after 1 min by electrocardiography",Other,18599160.0,
464,416878,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in Q-T interval at 1 mg/kg, iv after 1 min by electrocardiography",Other,18599160.0,
465,416879,6,1,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anaesthetized Wistar rat assessed as number of beats per minute at 1 mg/kg, iv after 1 min by electrocardiography",Other,18599160.0,
466,416880,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in P-Q-interval at 1 mg/kg, iv after 5 mins by electrocardiography",Other,18599160.0,
467,416881,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in QRS interval at 1 mg/kg, iv after 5 mins by electrocardiography",Other,18599160.0,
468,416882,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in Q-T interval at 1 mg/kg, iv after 5 mins by electrocardiography",Other,18599160.0,
469,416883,6,1,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anaesthetized Wistar rat assessed as number of beats per minute at 1 mg/kg, iv after 5 mins by electrocardiography",Other,18599160.0,
470,416884,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in P-Q-interval at 1 mg/kg, iv after 15 mins by electrocardiography",Other,18599160.0,
471,416885,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in QRS interval at 1 mg/kg, iv after 15 mins by electrocardiography",Other,18599160.0,
472,416886,3,3,,103197484,2585,Unspecified,,,,,"Effect on electrocardiogram in anaesthetized Wistar rat assessed as change in Q-T interval at 1 mg/kg, iv after 15 mins by electrocardiography",Other,18599160.0,
473,416887,6,1,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anaesthetized Wistar rat assessed as number of beats per minute at 1 mg/kg, iv after 15 mins by electrocardiography",Other,18599160.0,
474,416888,6,3,,103197484,2585,Unspecified,,,,,Antiarrhythmic activity against adrenaline-induced arrhythmia in iv dosed anaesthetized Wistar rat assessed as inhibition of premature ventricular beats pretreated 60 mins prior to adrenaline challenge,Other,18599160.0,
475,416890,6,2,,103197484,2585,Unspecified,,,,,Acute toxicity in iv dosed anaesthetized Wistar rat,Other,18599160.0,
476,416891,3,4,,103197484,2585,Unspecified,,,,,"Therapeutic index, ratio of LD50 for Wistar rat to antiarrhythmic ED50 for Wistar rat",Other,18599160.0,
477,425652,7,2,,103197484,2585,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
478,425653,7,2,,103197484,2585,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
479,434955,1,2,,49681735,2585,Inconclusive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
480,434959,1,1,,85789708,2585,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
481,434962,1,2,,49681735,2585,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
482,434973,1,3,,49681735,2585,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
483,434989,1,1,,49681735,2585,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
484,435003,1,3,,49681735,2585,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
485,435022,2,2,,49681735,2585,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
486,435030,1,2,,49681735,2585,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
487,435030,1,2,,49681735,2585,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
488,440092,3,3,,103197484,2585,Active,,,0.0022,Ki,Displacement of [3H]Prazosin from alpha1 adrenergic receptor in Wistar rat cerebral cortex membrane by liquid scintillation counting,Confirmatory,19647907.0,
489,440093,3,3,,103197484,2585,Active,,,0.0034,Ki,Displacement of [3H]Clonidine from alpha2 adrenergic receptor in Wistar rat cerebral cortex membrane by liquid scintillation counting,Confirmatory,19647907.0,
490,440094,3,3,,103197484,2585,Active,,,0.00081,Ki,Displacement of [3H]CGP12177 from beta-1 adrenergic receptor in Wistar rat cerebral cortex membrane by liquid scintillation counting,Confirmatory,19647907.0,
491,440096,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as P-Q intervals time at 1 mg/kg, iv after 1 min by electrocardiography",Other,19647907.0,
492,440097,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as P-Q intervals time at 1 mg/kg, iv after 5 mins by electrocardiography",Other,19647907.0,
493,440098,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as P-Q intervals time at 1 mg/kg, iv after 15 mins by electrocardiography",Other,19647907.0,
494,440284,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as QRS complex time at 1 mg/kg, iv after 1 min by electrocardiography",Other,19647907.0,
495,440285,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as QRS complex time at 1 mg/kg, iv after 5 mins by electrocardiography",Other,19647907.0,
496,440286,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as QRS complex time at 1 mg/kg, iv after 15 mins by electrocardiography",Other,19647907.0,
497,440287,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as Q-T intervals time at 1 mg/kg, iv after 1 min by electrocardiography",Other,19647907.0,
498,440288,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as Q-T intervals time at 1 mg/kg, iv after 5 mins by electrocardiography",Other,19647907.0,
499,440289,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as Q-T intervals time at 1 mg/kg, iv after 15 mins by electrocardiography",Other,19647907.0,
500,440290,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as heart beats per min at 1 mg/kg, iv after 1 min by electrocardiography",Other,19647907.0,
501,440291,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as heart beats per min at 1 mg/kg, iv after 5 mins by electrocardiography",Other,19647907.0,
502,440292,3,4,,103197484,2585,Unspecified,,,,,"Effect on heart rate in anesthetized Wistar rat assessed as heart beats per min at 1 mg/kg, iv after 15 mins by electrocardiography",Other,19647907.0,
503,440293,6,3,,103197484,2585,Unspecified,,,,,"Antiarrhythmic activity in Wistar rat assessed as inhibition of adrenaline-induced premature ventricular beats at 1 mg/kg, iv administered 15 mins before adrenaline challenge measured after 15 mins by electrocardiography",Other,19647907.0,
504,444050,7,1,,103197484,2585,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
505,444051,6,2,,103197484,2585,Unspecified,,,,,Total clearance in human,Other,20070106.0,
506,444052,6,2,,103197484,2585,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
507,444053,6,2,,103197484,2585,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
508,444054,6,1,,103197484,2585,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
509,444055,3,3,,103197484,2585,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
510,444056,3,3,,103197484,2585,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
511,444057,3,3,,103197484,2585,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
512,444058,6,2,,103197484,2585,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
513,449728,1,2,,49681735,2585,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
514,449739,1,2,,49681735,2585,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
515,449762,1,2,,49681735,2585,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
516,449763,1,3,,49681735,2585,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
517,449768,1,1,,49681735,2585,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
518,463079,1,2,,49681735,2585,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
519,463082,1,1,,49681735,2585,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
520,463104,1,2,,49681735,2585,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
521,463106,1,2,,90341342,2585,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
522,463111,1,1,,49681735,2585,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
523,463141,1,2,,49681735,2585,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
524,463165,1,1,,49681735,2585,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
525,463190,1,2,,49681735,2585,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
526,463195,1,2,,49681735,2585,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
527,463210,1,2,,49681735,2585,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
528,463212,1,1,,49681735,2585,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
529,463254,1,1,,26719722,2585,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
530,463254,1,1,,26719723,2585,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
531,485270,1,1,,49681735,2585,Active,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
532,485272,1,1,,49681735,2585,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
533,485273,2,1,,49681735,2585,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
534,485275,1,3,,49681735,2585,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
535,485281,1,1,,26719722,2585,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
536,485281,1,1,,26719723,2585,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
537,485281,1,1,,50112972,2585,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
538,485290,1,1,,26719722,2585,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
539,485290,1,1,,26719723,2585,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
540,485290,1,1,,50112972,2585,Inactive,20150581.0,,70.7946,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
541,485294,1,1,,26719722,2585,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
542,485294,1,1,,26719723,2585,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
543,485295,1,2,,90341342,2585,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
544,485297,1,1,,26719722,2585,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
545,485297,1,1,,26719723,2585,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
546,485297,1,1,,90341342,2585,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
547,485298,1,1,,26719722,2585,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
548,485298,1,1,,26719723,2585,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
549,485298,1,1,,90341342,2585,Inactive,,,23.1093,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
550,485313,1,2,,26719722,2585,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
551,485313,1,2,,26719723,2585,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
552,485313,1,2,,90341342,2585,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
553,485314,1,1,,26719722,2585,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
554,485314,1,1,,26719723,2585,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
555,485317,1,2,,49681735,2585,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
556,485341,1,1,,26719722,2585,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
557,485341,1,1,,26719723,2585,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
558,485342,1,2,,90341342,2585,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
559,485344,1,1,,26719722,2585,Active,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
560,485344,1,1,,26719723,2585,Active,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
561,485345,1,2,,90341342,2585,Inconclusive,,,18.3564,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
562,485346,1,1,,49681735,2585,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
563,485346,1,1,,49681735,2585,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
564,485347,1,2,,26719722,2585,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
565,485347,1,2,,26719723,2585,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
566,485353,2,1,,26719722,2585,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
567,485353,2,1,,26719723,2585,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
568,485358,1,1,,26719722,2585,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
569,485358,1,1,,26719723,2585,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
570,485364,1,1,,26719722,2585,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
571,485364,1,1,,26719723,2585,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
572,485366,1,2,,90341342,2585,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
573,485367,1,2,,26719722,2585,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
574,485367,1,2,,26719723,2585,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
575,485368,1,2,,90341342,2585,Inconclusive,72386991.0,3656265.0,8.4921,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
576,488772,1,1,,90341342,2585,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
577,488773,1,2,,90341342,2585,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
578,488816,1,1,,90341342,2585,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
579,488837,1,1,,26719722,2585,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
580,488837,1,1,,26719723,2585,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
581,488837,1,1,,90341342,2585,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
582,488847,1,3,,49681735,2585,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
583,488890,1,2,,49681735,2585,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
584,488922,1,2,,49681735,2585,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
585,488949,1,2,,90341342,2585,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
586,488953,1,1,,90341342,2585,Inconclusive,187960037.0,10951.0,39.8107,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
587,488960,1,1,,49681735,2585,Active,160333370.0,22068.0,,,Confirmatory screen for identification of compounds that inhibit transient receptor potential cation channel C6 (TRPC6),Screening,,
588,488961,1,1,,49681735,2585,Inactive,160333370.0,22068.0,,,Confirmatory screen for identification of compounds that activate transient receptor potential cation channel C6 (TRPC6),Screening,,
589,488975,1,2,,49681735,2585,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
590,488977,1,2,,49681735,2585,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
591,488978,1,1,,90341342,2585,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
592,488981,1,1,,90341342,2585,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
593,488982,1,1,,90341342,2585,Inactive,4503383.0,1812.0,2.5928,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
594,488983,1,1,,90341342,2585,Active,4503383.0,1812.0,8.9125,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
595,489030,2,1,,49681735,2585,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
596,489031,2,1,,49681735,2585,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
597,492947,1,1,,26719722,2585,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
598,492947,1,1,,26719723,2585,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
599,493011,1,1,,49681735,2585,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
600,493012,1,1,,49681735,2585,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
601,493014,1,1,,26719722,2585,Inconclusive,,,11.2202,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
602,493014,1,1,,26719723,2585,Inconclusive,,,22.3872,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
603,493036,1,2,,49681735,2585,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
604,493056,1,1,,26719722,2585,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
605,493056,1,1,,26719723,2585,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
606,493084,1,1,,26719722,2585,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
607,493084,1,1,,26719723,2585,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
608,493106,1,1,,90341342,2585,Inactive,116283940.0,79915.0,32.6294,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
609,493107,1,1,,90341342,2585,Inconclusive,116283940.0,79915.0,29.081,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
610,493153,1,1,,90341342,2585,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
611,493153,1,1,,90341342,2585,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
612,493164,1,2,,90341342,2585,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
613,493164,1,2,,90341342,2585,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
614,493164,1,2,,90341342,2585,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
615,504327,1,1,,26719722,2585,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
616,504327,1,1,,26719723,2585,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
617,504327,1,1,,50112972,2585,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
618,504327,1,1,,90341342,2585,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
619,504332,1,1,,26719722,2585,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
620,504332,1,1,,26719723,2585,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
621,504332,1,1,,90341342,2585,Inconclusive,168985070.0,,8.9125,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
622,504333,1,1,,26719722,2585,Active,6683500.0,29994.0,39.8107,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
623,504333,1,1,,26719723,2585,Inconclusive,6683500.0,29994.0,50.1187,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
624,504406,1,1,,49681735,2585,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
625,504408,2,1,,49681735,2585,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
626,504536,1,1,,90341342,2585,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
627,504547,1,1,,90341342,2585,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
628,504548,1,2,,90341342,2585,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
629,504651,1,1,,26719722,2585,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
630,504651,1,1,,26719723,2585,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
631,504652,1,1,,26719722,2585,Active,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
632,504652,1,1,,26719723,2585,Active,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
633,504660,1,1,,26719722,2585,Active,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
634,504660,1,1,,26719723,2585,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
635,504810,1,2,,26719722,2585,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
636,504810,1,2,,26719723,2585,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
637,504810,1,2,,90341342,2585,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
638,504812,1,2,,26719722,2585,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
639,504812,1,2,,26719723,2585,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
640,504812,1,2,,90341342,2585,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
641,504836,1,2,,90341342,2585,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
642,504842,1,1,,26719722,2585,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
643,504842,1,1,,26719723,2585,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
644,504845,1,1,,90341342,2585,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
645,504847,1,1,,50112972,2585,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
646,504847,1,1,,90341342,2585,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
647,504865,1,1,,90341342,2585,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
648,515780,5,1,,103197484,2585,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
649,540209,4,3,,103197484,2585,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
650,540210,4,3,,103197484,2585,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
651,540211,2,5,,103197484,2585,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
652,540212,4,3,,103197484,2585,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
653,540213,4,3,,103197484,2585,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
654,540256,1,2,,90341342,2585,Inconclusive,,,12.99,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
655,540275,1,1,,26719722,2585,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
656,540275,1,1,,26719723,2585,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
657,540276,1,2,,26719722,2585,Active,420597.0,,11.5774,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
658,540276,1,2,,26719723,2585,Active,420597.0,,11.5774,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
659,540276,1,2,,50112972,2585,Active,420597.0,,11.5774,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
660,540276,1,2,,50112973,2585,Active,420597.0,,11.5774,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
661,540276,1,2,,90341342,2585,Active,420597.0,,11.5774,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
662,540277,1,1,,26719722,2585,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
663,540277,1,1,,26719723,2585,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
664,547621,4,3,,103197484,2585,Active,,,31.0,EC50,Cytotoxicity against BESM cells after 88 hrs by HTS assay,Confirmatory,20547819.0,
665,547622,4,2,,103197484,2585,Active,,,8.0,EC50,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,Confirmatory,20547819.0,
666,547804,1,3,,103197484,2585,Unspecified,,,,,"Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells",Other,20547819.0,
667,576612,7,5,,103197484,2585,Active,7531135.0,3757.0,12.5893,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
668,588211,2,3,,103197484,2585,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
669,588212,2,3,,103197484,2585,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
670,588213,2,3,,103197484,2585,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
671,588214,2,3,,103197484,2585,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
672,588215,2,3,,103197484,2585,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
673,588216,2,3,,103197484,2585,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
674,588217,2,3,,103197484,2585,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
675,588218,2,3,,103197484,2585,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
676,588219,2,3,,103197484,2585,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
677,588342,1,1,,26719722,2585,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
678,588342,1,1,,26719723,2585,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
679,588349,1,1,,90341342,2585,Inconclusive,,,31.6228,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
680,588378,1,1,,90341342,2585,Inconclusive,171543895.0,6311.0,19.9526,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
681,588453,1,1,,90341342,2585,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
682,588456,1,1,,90341342,2585,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
683,588511,1,2,,49681735,2585,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
684,588579,1,1,,50112972,2585,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
685,588579,1,1,,90341342,2585,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
686,588627,1,1,,49681735,2585,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
687,588675,1,1,,49681735,2585,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
688,588676,1,1,,49681735,2585,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
689,588795,1,1,,90341342,2585,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
690,589068,1,10,,103197484,2585,Unspecified,136729.0,54658.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A1,Other,,
691,589077,1,10,,103197484,2585,Unspecified,6175083.0,7363.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B4,Other,,
692,589078,1,10,,103197484,2585,Unspecified,136727.0,7364.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B7,Other,,
693,602332,1,1,,50112972,2585,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
694,602332,1,1,,90341342,2585,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
695,624101,1,2,,85789499,2585,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
696,624137,1,1,,85789499,2585,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
697,624146,1,1,,90341342,2585,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
698,624147,1,1,,90341342,2585,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
699,624148,1,2,,90341342,2585,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
700,624149,1,1,,90341342,2585,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
701,624151,1,1,,85789499,2585,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
702,624156,1,1,,85789708,2585,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
703,624260,1,1,,85789499,2585,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
704,624349,1,2,,92307922,2585,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
705,624349,1,2,,92308493,2585,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
706,624349,1,2,,92308705,2585,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
707,624455,1,1,,90341342,2585,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
708,625144,5,5,,103197484,2585,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
709,625145,4,7,,103197484,2585,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
710,625146,5,5,,103197484,2585,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
711,625147,4,7,,103197484,2585,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
712,625148,4,7,,103197484,2585,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
713,625149,4,7,,103197484,2585,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
714,625150,5,5,,103197484,2585,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
715,625151,4,7,,103197484,2585,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
716,625152,4,7,,103197484,2585,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
717,625153,4,7,,103197484,2585,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
718,625154,4,7,,103197484,2585,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
719,625155,4,7,,103197484,2585,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
720,625156,1,9,,103197484,2585,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
721,625157,6,2,,103197484,2585,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
722,625158,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
723,625159,5,5,,103197484,2585,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
724,625160,1,9,,103197484,2585,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
725,625161,4,7,,103197484,2585,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
726,625162,4,7,,103197484,2585,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
727,625163,4,7,,103197484,2585,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
728,625164,1,6,,103197484,2585,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
729,625165,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
730,625166,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
731,625167,5,5,,103197484,2585,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
732,625168,4,7,,103197484,2585,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
733,625169,1,6,,103197484,2585,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
734,625170,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
735,625171,4,7,,103197484,2585,Active,7531135.0,3757.0,4.1193,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
736,625172,4,7,,103197484,2585,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
737,625173,5,5,,103197484,2585,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
738,625174,5,5,,103197484,2585,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
739,625175,5,5,,103197484,2585,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
740,625176,1,9,,103197484,2585,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
741,625177,5,5,,103197484,2585,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
742,625178,5,5,,103197484,2585,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
743,625179,1,9,,103197484,2585,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
744,625180,5,5,,103197484,2585,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
745,625181,5,5,,103197484,2585,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
746,625182,5,5,,103197484,2585,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
747,625183,5,5,,103197484,2585,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
748,625184,5,5,,103197484,2585,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
749,625185,5,5,,103197484,2585,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
750,625186,5,5,,103197484,2585,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
751,625187,5,5,,103197484,2585,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
752,625188,1,9,,103197484,2585,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
753,625189,1,7,,103197484,2585,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
754,625190,4,5,,103197484,2585,Active,,,0.00584,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
755,625191,4,7,,103197484,2585,Active,112815.0,25075.0,1.295,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
756,625192,4,7,,103197484,2585,Active,543727.0,3356.0,0.41,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
757,625193,5,5,,103197484,2585,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
758,625194,4,7,,103197484,2585,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
759,625195,4,7,,103197484,2585,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
760,625196,5,6,,103197484,2585,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
761,625197,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
762,625198,4,7,,103197484,2585,Active,1168247.0,29412.0,0.007790000000000001,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
763,625199,4,7,,103197484,2585,Active,543734.0,24173.0,0.00355,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
764,625200,4,7,,103197484,2585,Active,1168243.0,146.0,0.0018,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
765,625201,4,7,,103197484,2585,Active,1351829.0,150.0,0.106,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
766,625202,4,7,,103197484,2585,Active,613504690.0,151.0,0.094,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
767,625203,4,7,,103197484,2585,Active,20141211.0,152.0,0.09,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
768,625204,4,7,,103197484,2585,Active,48429211.0,153.0,0.000178,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
769,625205,4,7,,103197484,2585,Active,296439450.0,154.0,0.000241,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
770,625206,4,7,,103197484,2585,Active,461604.0,155.0,0.0041600000000000005,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
771,625207,4,7,,103197484,2585,Active,128616.0,6530.0,0.5379999999999999,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
772,625208,5,5,,103197484,2585,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
773,625209,4,7,,103197484,2585,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
774,625210,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
775,625211,1,6,,103197484,2585,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
776,625212,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
777,625213,4,7,,103197484,2585,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
778,625214,1,9,,103197484,2585,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
779,625215,3,4,,103197484,2585,Active,,,0.621,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
780,625216,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
781,625217,4,7,,103197484,2585,Active,1168220.0,3357.0,0.023,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
782,625218,4,7,,103197484,2585,Active,112816.0,3358.0,0.115,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
783,625219,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
784,625220,4,7,,103197484,2585,Active,6224984.0,100135548.0,1.088,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
785,625221,4,7,,103197484,2585,Active,1703010.0,3362.0,1.5190000000000001,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
786,625222,4,7,,103197484,2585,Active,400630.0,6532.0,0.221,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
787,625223,4,7,,103197484,2585,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
788,625224,3,4,,103197484,2585,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
789,625225,3,4,,103197484,2585,Active,,,0.455,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
790,625226,4,7,,103197484,2585,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
791,625227,4,7,,103197484,2585,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
792,625228,4,7,,103197484,2585,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
793,625229,5,5,,103197484,2585,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
794,625230,1,6,,103197484,2585,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
795,625231,4,7,,103197484,2585,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
796,625232,1,9,,103197484,2585,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
797,625233,4,7,,103197484,2585,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
798,625234,3,4,,103197484,2585,Active,,,0.389,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
799,625235,4,7,,103197484,2585,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
800,625236,5,5,,103197484,2585,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
801,625237,4,7,,103197484,2585,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
802,625238,4,7,,103197484,2585,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
803,625239,4,7,,103197484,2585,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
804,625240,1,9,,103197484,2585,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
805,625241,4,7,,103197484,2585,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
806,625242,4,7,,103197484,2585,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
807,625243,5,5,,103197484,2585,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
808,625244,5,5,,103197484,2585,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
809,625245,5,5,,103197484,2585,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
810,625246,1,9,,103197484,2585,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
811,625247,5,5,,103197484,2585,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
812,625248,5,5,,103197484,2585,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
813,625249,5,5,,103197484,2585,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
814,625250,5,5,,103197484,2585,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
815,625251,5,5,,103197484,2585,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
816,625252,4,7,,103197484,2585,Active,118228.0,1812.0,1.4980000000000002,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
817,625253,4,7,,103197484,2585,Active,118206.0,1813.0,0.146,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
818,625254,4,7,,103197484,2585,Active,1169206.0,1814.0,0.5770000000000001,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
819,625255,4,7,,103197484,2585,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
820,625256,4,7,,103197484,2585,Active,266667.0,6531.0,0.845,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
821,625257,4,7,,103197484,2585,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
822,625258,4,7,,103197484,2585,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
823,625259,4,7,,103197484,2585,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
824,625260,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
825,625261,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
826,625262,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
827,625263,4,7,,103197484,2585,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
828,625264,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
829,625265,1,6,,103197484,2585,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
830,625266,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
831,625267,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
832,625268,4,2,,103197484,2585,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
833,625268,4,2,,103197484,2585,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
834,625268,4,2,,103197484,2585,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
835,625268,4,2,,103197484,2585,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
836,625269,4,7,,103197484,2585,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
837,625270,4,7,,103197484,2585,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
838,625271,5,5,,103197484,2585,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
839,625272,3,4,,103197484,2585,Active,,,1.92,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
840,625273,4,6,,103197484,2585,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
841,625274,1,6,,103197484,2585,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
842,625275,3,4,,103197484,2585,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
843,625279,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
844,625280,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
845,625281,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
846,625282,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
847,625283,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
848,625284,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
849,625285,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
850,625286,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
851,625287,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
852,625288,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
853,625289,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
854,625290,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
855,625291,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
856,625292,1,3,,103197484,2585,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
857,651635,1,3,,90341342,2585,Inconclusive,171543895.0,6311.0,31.6228,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
858,651828,1,2,,92308493,2585,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
859,651828,1,2,,92308705,2585,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
860,651828,1,2,,121361219,2585,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
861,652106,1,1,,90341342,2585,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
862,679589,1,8,,103197484,2585,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Carvedilol: 50 uM) in MDR1-expressing LLC-PK1 cells",Other,11895100.0,
863,680310,1,8,,103197484,2585,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein intracellular accumulation (Calcein: 50 mg/L, Carvedilol: 10 uM) in Hs578T-Dox cells",Other,10571255.0,
864,681126,3,6,,103197484,2585,Unspecified,238054374.0,5243.0,6.6,IC50,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
865,681127,3,6,,103197484,2585,Unspecified,238054374.0,5243.0,6.0,IC50,TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
866,681131,3,6,,103197484,2585,Unspecified,238054374.0,5243.0,4.6,IC50,TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
867,687035,1,1,,163564301,2585,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
868,687037,1,3,,163564301,2585,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
869,717844,1,7,,103197484,2585,Unspecified,939108065.0,209176.0,,,Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control,Other,23122865.0,
870,720532,1,1,,50112972,2585,Inconclusive,420597.0,,15.8489,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
871,720533,1,1,,50112972,2585,Inconclusive,,,25.1189,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
872,720538,1,2,,90341342,2585,Inconclusive,220983390.0,410.0,0.0269,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
873,720554,1,3,,92308493,2585,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
874,720559,1,2,,90341342,2585,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
875,720572,1,2,,90341342,2585,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
876,720573,1,2,,90341342,2585,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
877,720641,1,2,,92307922,2585,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
878,720641,1,2,,92308493,2585,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
879,720641,1,2,,92308705,2585,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
880,720717,1,3,,92307922,2585,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
881,720717,1,3,,92308493,2585,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
882,720717,1,3,,92308705,2585,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
883,721748,2,5,,103197484,2585,Inactive,74727585.0,146802.0,,IC50,Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
884,721751,2,5,,103197484,2585,Active,313104182.0,6582.0,7.5,IC50,Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
885,721753,1,6,,103197484,2585,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
886,721754,2,5,,103197484,2585,Unspecified,74731723.0,55244.0,92.4,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
887,722794,1,3,,103197484,2585,Unspecified,,,,,Antiarrhythmic activity in iv dosed Wistar rat adrenaline-induced arrhythmia model assessed as reduction of heart-rhythm disturbance administered 15 mins adrenaline-challenge,Other,23245804.0,
888,742483,1,6,,103197484,2585,Active,461604.0,155.0,,,Adrenergic receptor beta antagonist,Other,,
889,742483,1,6,,103197484,2585,Active,48429211.0,153.0,,,Adrenergic receptor beta antagonist,Other,,
890,742483,1,6,,103197484,2585,Active,296439450.0,154.0,,,Adrenergic receptor beta antagonist,Other,,
891,742496,2,2,,103197484,2585,Active,1168243.0,146.0,,,Adrenergic receptor alpha-1 antagonist,Other,,
892,742496,2,2,,103197484,2585,Active,1168246.0,148.0,,,Adrenergic receptor alpha-1 antagonist,Other,,
893,742496,2,2,,103197484,2585,Active,116241241.0,147.0,,,Adrenergic receptor alpha-1 antagonist,Other,,
894,743205,1,1,,90341342,2585,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
895,743205,1,1,,90341342,2585,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
896,743206,1,1,,90341342,2585,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
897,743206,1,1,,90341342,2585,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
898,743207,1,1,,90341342,2585,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
899,743207,1,1,,90341342,2585,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
900,743244,1,1,,90341342,2585,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
901,743268,1,1,,172080290,2585,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
902,743270,1,1,,172080290,2585,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
903,743271,1,1,,172080290,2585,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
904,743272,1,1,,172080290,2585,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
905,743281,1,1,,46386749,2585,Inactive,1778357.0,22341.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
906,743281,1,1,,46386749,2585,Inactive,219520294.0,8828.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
907,743344,1,1,,174007145,2585,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
908,743345,1,1,,174007145,2585,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
909,743346,1,1,,174007145,2585,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
910,743347,1,1,,174007145,2585,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
911,748695,2,1,,103197484,2585,Active,112927.0,351.0,30.0,IC50,Inhibition of amyloid beta (1 to 40) (unknown origin) fibril formation after 18 hrs by DELFIA,Confirmatory,23484434.0,
912,777140,1,1,,103197484,2585,Active,,,15.9,IC50,Inhibition of RyR2 R4496C mutant (unknown origin)-mediated store-overload induced calcium release expressed in HEK293 cells after 8 to 10 mins by fura-2/AM dye-based fluorescence assay,Confirmatory,24124794.0,
913,781326,1,2,,103197484,2585,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
914,923411,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020205,Other,,
915,923412,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020205,Other,,
916,923413,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020205,Other,,
917,923414,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020205,Other,,
918,923415,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020205,Other,,
919,923416,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020205,Other,,
920,923669,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020205,Other,,
921,923670,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020205,Other,,
922,923671,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020205",Other,,
923,923672,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020205,Other,,
924,923673,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020205,Other,,
925,923674,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020205,Other,,
926,923675,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020205,Other,,
927,924258,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020205,Other,,
928,924259,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020205,Other,,
929,924260,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020205,Other,,
930,924261,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020205,Other,,
931,924262,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020205,Other,,
932,924263,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020205,Other,,
933,928012,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020205,Other,,
934,928013,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020205,Other,,
935,928014,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020205,Other,,
936,928015,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020205,Other,,
937,928016,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020205,Other,,
938,928017,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020205,Other,,
939,928018,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020205,Other,,
940,928019,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020205,Other,,
941,928020,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020205,Other,,
942,928021,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020205,Other,,
943,928022,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020205,Other,,
944,928023,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020205",Other,,
945,928024,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020205,Other,,
946,928025,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020205,Other,,
947,928026,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020205,Other,,
948,928027,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020205,Other,,
949,928028,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020205,Other,,
950,928029,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020205,Other,,
951,928030,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020205,Other,,
952,954691,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020205,Other,,
953,954692,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020205,Other,,
954,955280,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020205,Other,,
955,955281,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020205,Other,,
956,955282,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020205,Other,,
957,955283,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020205,Other,,
958,955284,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020205,Other,,
959,955285,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020205,Other,,
960,955286,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020205,Other,,
961,955287,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020205,Other,,
962,955288,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020205,Other,,
963,955289,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020205,Other,,
964,955290,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020205,Other,,
965,955291,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020205,Other,,
966,955292,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020205,Other,,
967,955293,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020205,Other,,
968,955294,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020205,Other,,
969,955295,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020205,Other,,
970,955296,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020205,Other,,
971,967033,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020205,Other,,
972,967034,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020205,Other,,
973,967035,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020205,Other,,
974,967036,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020205,Other,,
975,967037,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020205,Other,,
976,967038,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020205,Other,,
977,967039,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020205,Other,,
978,967040,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020205,Other,,
979,967041,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020205,Other,,
980,967042,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020205,Other,,
981,967043,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020205,Other,,
982,967044,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020205,Other,,
983,967045,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020205,Other,,
984,967046,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020205,Other,,
985,969070,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020205,Other,,
986,969702,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020205,Other,,
987,969703,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020205,Other,,
988,969704,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020205,Other,,
989,969705,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020205,Other,,
990,982696,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
991,982697,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020205,Other,,
992,982698,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020205",Other,,
993,982699,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
994,982700,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
995,982701,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020205",Other,,
996,982702,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020205,Other,,
997,982703,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
998,982704,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
999,982705,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1000,982706,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020205",Other,,
1001,982707,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020205,Other,,
1002,982708,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020205",Other,,
1003,982709,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020205",Other,,
1004,982710,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1005,982711,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020205",Other,,
1006,982712,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020205",Other,,
1007,982713,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020205",Other,,
1008,982714,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020205,Other,,
1009,982715,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1010,983183,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020205",Other,,
1011,983184,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020205,Other,,
1012,983185,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1013,983186,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020205",Other,,
1014,983187,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1015,983188,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1016,983189,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1017,983190,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020205",Other,,
1018,984676,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1019,984677,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020205",Other,,
1020,984678,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020205",Other,,
1021,984679,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020205",Other,,
1022,984680,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1023,984681,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1024,984682,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1025,984683,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020205,Other,,
1026,984684,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020205,Other,,
1027,984685,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020205",Other,,
1028,984686,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020205,Other,,
1029,984687,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020205",Other,,
1030,984688,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1031,984689,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020205",Other,,
1032,984690,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020205",Other,,
1033,984691,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1034,984692,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020205",Other,,
1035,984693,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1036,984694,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020205",Other,,
1037,984695,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020205",Other,,
1038,984696,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1039,984697,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1040,984698,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1041,984699,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1042,984700,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1043,985168,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1044,985169,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020205",Other,,
1045,985170,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1046,985171,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1047,985172,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020205",Other,,
1048,985173,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1049,1015514,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020205",Other,,
1050,1015515,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1051,1015516,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1052,1015517,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1053,1015518,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020205,Other,,
1054,1015519,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020205",Other,,
1055,1015520,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020205,Other,,
1056,1015521,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020205",Other,,
1057,1015522,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1058,1015523,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020205",Other,,
1059,1015524,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020205",Other,,
1060,1015525,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1061,1015553,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020205",Other,,
1062,1015554,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020205",Other,,
1063,1015555,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020205",Other,,
1064,1015556,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1065,1015557,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020205",Other,,
1066,1015558,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020205",Other,,
1067,1015559,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020205",Other,,
1068,1015560,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020205,Other,,
1069,1015561,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1070,1015562,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020205",Other,,
1071,1015563,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020205",Other,,
1072,1015564,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1073,1015565,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020205",Other,,
1074,1015566,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020205",Other,,
1075,1015567,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020205",Other,,
1076,1015568,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1077,1015569,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020205",Other,,
1078,1015570,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020205",Other,,
1079,1015571,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020205,Other,,
1080,1015572,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1081,1015573,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020205",Other,,
1082,1015574,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1083,1015575,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1084,1015576,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1085,1015577,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020205",Other,,
1086,1015578,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1087,1015579,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1088,1015580,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020205",Other,,
1089,1017394,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020205",Other,,
1090,1017395,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1091,1017396,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020205",Other,,
1092,1017397,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020205",Other,,
1093,1017398,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1094,1017399,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1095,1017400,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1096,1017401,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1097,1017402,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1098,1017403,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1099,1017404,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020205",Other,,
1100,1017405,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1101,1017406,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1102,1017407,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020205",Other,,
1103,1017408,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1104,1017409,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020205,Other,,
1105,1017410,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020205,Other,,
1106,1017411,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020205",Other,,
1107,1017412,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1108,1017413,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1109,1017414,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020205",Other,,
1110,1017415,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020205,Other,,
1111,1017416,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1112,1017417,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1113,1018002,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1114,1018003,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020205",Other,,
1115,1018004,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020205,Other,,
1116,1018005,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1117,1018006,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020205",Other,,
1118,1018007,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020205",Other,,
1119,1018008,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1120,1018009,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020205",Other,,
1121,1018010,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020205",Other,,
1122,1018011,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020205",Other,,
1123,1018012,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020205,Other,,
1124,1018013,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1125,1018014,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020205",Other,,
1126,1018015,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020205,Other,,
1127,1018016,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1128,1018017,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020205",Other,,
1129,1019889,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1130,1019890,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1131,1019891,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1132,1019892,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020205",Other,,
1133,1019893,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1134,1019894,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1135,1019895,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020205,Other,,
1136,1019896,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1137,1019897,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020205",Other,,
1138,1019898,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020205",Other,,
1139,1019899,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1140,1019900,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1141,1019901,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1142,1019902,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1143,1019903,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020205",Other,,
1144,1019904,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020205",Other,,
1145,1019905,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1146,1019906,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020205",Other,,
1147,1019907,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020205",Other,,
1148,1020491,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020205",Other,,
1149,1020492,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020205",Other,,
1150,1020493,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020205,Other,,
1151,1020494,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020205,Other,,
1152,1020495,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020205",Other,,
1153,1020496,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020205,Other,,
1154,1020497,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020205",Other,,
1155,1020498,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1156,1020499,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020205",Other,,
1157,1020500,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020205",Other,,
1158,1020501,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1159,1020502,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020205",Other,,
1160,1020503,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1161,1020504,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020205",Other,,
1162,1020505,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020205",Other,,
1163,1020506,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020205",Other,,
1164,1020507,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020205",Other,,
1165,1020508,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020205,Other,,
1166,1020509,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1167,1020510,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1168,1020511,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1169,1022379,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1170,1022380,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1171,1022381,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1172,1022382,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1173,1022383,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020205",Other,,
1174,1022384,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1175,1022385,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020205",Other,,
1176,1022386,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020205",Other,,
1177,1022387,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020205",Other,,
1178,1022388,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020205",Other,,
1179,1022389,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020205",Other,,
1180,1022390,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020205",Other,,
1181,1022391,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020205",Other,,
1182,1022392,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020205",Other,,
1183,1022393,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020205",Other,,
1184,1022977,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020205",Other,,
1185,1022978,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020205,Other,,
1186,1022979,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020205",Other,,
1187,1022980,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020205",Other,,
1188,1022981,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1189,1022982,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020205",Other,,
1190,1022983,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020205",Other,,
1191,1022984,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1192,1022985,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1193,1022986,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020205",Other,,
1194,1022987,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020205",Other,,
1195,1022988,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020205",Other,,
1196,1022989,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020205",Other,,
1197,1022990,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020205",Other,,
1198,1022991,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1199,1022992,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020205",Other,,
1200,1022993,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020205",Other,,
1201,1022994,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020205,Other,,
1202,1022995,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020205",Other,,
1203,1022996,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1204,1022997,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020205",Other,,
1205,1022998,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020205",Other,,
1206,1022999,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020205",Other,,
1207,1023000,1,3,,103197484,2585,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020205,Other,,
1208,1023001,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020205",Other,,
1209,1024835,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020205",Other,,
1210,1024836,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020205",Other,,
1211,1024837,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020205",Other,,
1212,1024865,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1213,1024866,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020205",Other,,
1214,1024867,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020205",Other,,
1215,1024868,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020205",Other,,
1216,1024869,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1217,1024870,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020205",Other,,
1218,1024871,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020205",Other,,
1219,1024872,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020205",Other,,
1220,1024873,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020205",Other,,
1221,1024874,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020205",Other,,
1222,1024875,1,3,,103197484,2585,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020205",Other,,
1223,1057862,1,1,,103197484,2585,Active,,,2.28,EC50,Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA,Confirmatory,24183589.0,
1224,1057863,1,1,,103197484,2585,Active,,,6.1,LC50,Cytotoxicity against mouse dividing ScN2a-cl3 cells assessed as cell viability after 5 days by calcein-AM staining-based fluorescence assay,Confirmatory,24183589.0,
1225,1057864,1,1,,103197484,2585,Unspecified,,,,,Ratio of LC50 for dividing mouse ScN2a-cl3 cells to EC50 for inhibition of RML prion protein,Other,24183589.0,
1226,1079931,1,1,,103197484,2585,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1227,1079932,1,1,,103197484,2585,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1228,1079933,1,1,,103197484,2585,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1229,1079934,1,1,,103197484,2585,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1230,1079935,1,1,,103197484,2585,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1231,1079936,1,1,,103197484,2585,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1232,1079937,1,1,,103197484,2585,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1233,1079938,1,1,,103197484,2585,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1234,1079939,1,1,,103197484,2585,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1235,1079940,1,1,,103197484,2585,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1236,1079941,1,1,,103197484,2585,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1237,1079942,1,1,,103197484,2585,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1238,1079943,1,1,,103197484,2585,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1239,1079944,1,1,,103197484,2585,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1240,1079945,1,1,,103197484,2585,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1241,1079946,1,1,,103197484,2585,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1242,1079947,1,1,,103197484,2585,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1243,1079948,1,1,,103197484,2585,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1244,1079949,1,1,,103197484,2585,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1245,1097336,1,3,,103197484,2585,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
1246,1117319,1,2,,26719722,2585,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1247,1117319,1,2,,26719722,2585,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1248,1117319,1,2,,26719723,2585,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1249,1117319,1,2,,26719723,2585,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1250,1159387,1,2,,103197484,2585,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
1251,1159390,1,2,,103197484,2585,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1252,1159394,1,2,,103197484,2585,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
1253,1159396,1,2,,103197484,2585,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
1254,1159524,1,1,,50112972,2585,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1255,1159580,2,1,,268735024,2585,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1256,1159607,2,1,,312310112,2585,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1257,1159620,1,1,,103197484,2585,Active,,,,,Summary of drug indications.,Other,,
1258,1222388,1,2,,103197484,2585,Active,136729.0,54658.0,27.0,IC50,Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method,Confirmatory,21030469.0,
1259,1222389,1,2,,103197484,2585,Active,136729.0,54658.0,12.0,IC50,Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method,Confirmatory,21030469.0,
1260,1224818,1,1,,312344472,2585,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
1261,1224819,1,1,,312344472,2585,Inconclusive,325495545.0,2101.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1262,1224820,1,1,,312344472,2585,Inactive,325495545.0,2101.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1263,1224821,1,1,,312344472,2585,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1264,1224822,1,1,,312344472,2585,Inconclusive,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
1265,1224823,1,1,,312344472,2585,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1266,1224824,1,1,,174007145,2585,Inactive,,,37.2212,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1267,1224825,1,1,,174007145,2585,Inactive,,,8.3328,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1268,1224857,2,1,,174007145,2585,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1269,1224857,2,1,,312344472,2585,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1270,1224859,2,1,,90341342,2585,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1271,1224859,2,1,,174007145,2585,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1272,1224863,1,1,,176484088,2585,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1273,1224863,1,1,,316918933,2585,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1274,1224863,1,1,,316918945,2585,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1275,1224905,2,1,,92308705,2585,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1276,1224905,2,1,,92308705,2585,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1277,1224905,2,1,,121361219,2585,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1278,1224905,2,1,,121361219,2585,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1279,1227382,1,1,,103197484,2585,Active,,,17.378,IC50,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay,Confirmatory,,
1280,1227383,1,1,,103197484,2585,Unspecified,,,85.0,IC50,Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay,Confirmatory,,
1281,1257224,1,1,,103197484,2585,Active,,,10.4,IC50,Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins,Confirmatory,26592812.0,
1282,1257225,1,1,,103197484,2585,Active,,,22.1,IC50,Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins in presence of 0.01% triton X-100,Confirmatory,26592812.0,
1283,1257226,1,1,,103197484,2585,Inactive,,,,,Inhibition of Trichomonas vaginalis uridine ribohydrolase after 40 mins,Other,26592812.0,
1284,1257352,1,1,,103197484,2585,Unspecified,116411.0,100144322.0,3.59,IC50,Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in rabbit ventricular myocytes,Confirmatory,,
1285,1259252,1,1,,174007145,2585,Inconclusive,169655958.0,,18.6548,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1286,1259253,1,1,,174007145,2585,Inconclusive,169655958.0,,20.930999999999997,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1287,1259255,1,1,,174007145,2585,Inconclusive,169655958.0,,6.619,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1288,1259256,1,1,,174007145,2585,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1289,1259310,1,1,,46386749,2585,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1290,1259310,1,1,,333472951,2585,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1291,1259310,1,1,,333473154,2585,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1292,1259325,1,2,,336955363,2585,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1293,1259370,2,2,,175607590,2585,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1294,1259370,2,2,,175607590,2585,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1295,1259370,2,2,,175607590,2585,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1296,1259389,1,1,,124658917,2585,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
1297,1259389,1,1,,175607590,2585,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
1298,1259406,1,1,,363920111,2585,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
1299,1259406,1,1,1.0,363920111,2585,Inactive,26638650.0,3778.0,-0.029101099999999998,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
1300,1259406,1,1,2.0,363920111,2585,Active,4758626.0,3779.0,0.26037,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1301,1259406,1,1,3.0,363920111,2585,Active,5031823.0,10242.0,-0.290137,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
1302,1259406,1,1,4.0,363920111,2585,Active,26051275.0,27345.0,0.357537,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
1303,1259406,1,1,5.0,363920111,2585,Active,160410009.0,389816.0,0.203677,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1304,1259406,1,1,6.0,363920111,2585,Active,26638650.0,3778.0,-0.173925,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
1305,1259406,1,1,7.0,363920111,2585,Active,4758626.0,3779.0,0.386074,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1306,1259406,1,1,8.0,363920111,2585,Inactive,5031823.0,10242.0,0.0657067,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
1307,1259406,1,1,9.0,363920111,2585,Active,26051275.0,27345.0,0.21594899999999997,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
1308,1259406,1,1,10.0,363920111,2585,Inactive,5031823.0,10242.0,0.044335900000000004,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
1309,1259413,1,2,,46386749,2585,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
1310,1259416,1,2,,340079660,2585,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1311,1259416,1,2,,375174994,2585,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1312,1259421,1,1,,340079660,2585,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1313,1259421,1,1,,375174994,2585,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1314,1259423,1,2,,354973705,2585,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1315,1259423,1,2,,355018611,2585,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
